Both preclinical studies and clinical trials have shown that antiangiogenic agents could sensitize patients to ICIs via reprogramming the tumor microenvironment, leading to the approval of bevacizumab (anti-VEGFA) plus atezolizumab or sintilimab (anti-PD-L1/PD-1) in the first-line settings, based on the superior OS and progression-free survival (PFS) versus current standard care (sorafenib) for patients with unresectable HCC (8–11). Here, PDCD1 is linked to hepatocellular carcinoma.